AcuityMD, a Boston, MA–based AI platform for medtech, has raised $80 million in Series C funding, pushing its valuation to $955 million.

Investors 

The round was led by StepStone Group, with participation from Benchmark, Redpoint Ventures, ICONIQ, and Atreides Management, bringing AcuityMD's total capital raised to over $160 million.

StepStone Group is a global investment firm specializing in private markets, including private equity, private debt, real estate, and infrastructure. Founded in 2007 and headquartered in New York, the firm operates across three main strategies: primary fund investments (committing capital to other VC/PE funds), secondary investments (buying existing stakes in funds or portfolios), and direct co-investments alongside fund managers. 

AcuityMD Use of Funds 

The company will use the funding to enhance its AI capabilities, deepen its proprietary MedTech data ontology, and expand its platform into broader workflows beyond commercial use cases. 

About AcuityMD 

Led by CEO Mike Monovoukas, AcuityMD is a technology company that provides an AI-driven platform tailored for the medical device industry. It aggregates and structures fragmented healthcare data, such as claims, regulatory filings, and market signals, into a proprietary ontology that maps relationships among physicians, facilities, procedures, and reimbursement dynamics. Its latest innovation, AcuityAI, builds on this foundation to deliver contextual, real-time intelligence to sales teams and decision-makers. Headquartered in Boston, Massachusetts, AcuityMD serves over 400 MedTech companies. 

Funding Details 

Company: AcuityMD, Inc. 

Raised: $80.0M 

Round: Series C 

Funding Date: April 2026 

Lead Investor: StepStone Group 

Additional Investors: Benchmark, Redpoint Ventures, ICONIQ, Atreides Management 

Company Website: https://www.acuitymd.com/  

Software Category: HealthTech / AI / MedTech Intelligence Platform 

Source: https://www.businesswire.com/news/home/20260421820643/en/